Historically, FDA issues never get resolved in two-three months. They take a prolonged period, almost a year or so. But depending on how that goes, I think that will determine the performance.
Hyundai India’s weak debut one more among mega IPOs
“Since the issue size was large, it took away the possibility of the share price seeing any scarcity premium on the listing day,” said Mrunmayee